

March 28, 2013

Immunicum conducts a private placement of 8,8 million SEK

Due to the large interest in investing in Immunicum that has been shown, on March 28, 2013, the Board of Directors of the Company decided to conduct a private placement to professional investors bringing in 8,8 million SEK. This was announced in the Company's investment memorandum for the recent listing's issuance of 21,4 million SEK. The largest of these professional investors is LMK Forward AB.

Immunicum's CEO, Jamal El-Mosleh said:

"We are happy to see that larger professional investors are showing confidence in the technologies that Immunicum is working with. The extra financing will be able to contribute to an increased pace in the planning of the upcoming clinical phase II-trial in renal cancer."

G&W Kapitalförvaltning acted as financial advisor and has been selected as Immunicum's Certified Adviser for the Company's upcoming listing on NASDAQ OMX First North. Preliminary first day of trading is April 22:nd.

For further information see Immunicum's website: www.immunicum.se or contact Jamal El-Mosleh, CEO Immunicum AB, tel: 031-772 81 50, 0703-31 90 51.

Email: jamal.el-mosleh@immunicum.com.

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum's products can be produced in large scale. The vaccines have proven efficacy in animal studies and are now undergoing tests on patients.